User: Guest

CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT

Global Market Trajectory & Analytics

MCP-6220

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4322

Interactions with Platform & by Email *

INTERACTIONS

778

Unique # Participated *

PARTICIPANTS

132

Responses Validated *

VALIDATIONS

59

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    120

  •  PAGES

    203

  •  EDITION

    16

  •  PRICE

    USD $5450


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Chronic Obstructive Pulmonary Disease Treatment estimated at US$16.7 Billion in the year 2020, is projected to reach a revised size of US$21 Billion by 2027, growing at a CAGR of 3.4% over the analysis period 2020-2027. Bronchodilators, one of the segments analyzed in the report, is projected to record a 3.8% CAGR and reach US$5.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Combination segment is readjusted to a revised 3.8% CAGR for the next 7-year period.
The Chronic Obstructive Pulmonary Disease Treatment market in the U.S. is estimated at US$4.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.
In the global Phosphodiesterase Type 4 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 2.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.9 Billion in the year 2020 will reach a projected size of US$2.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.9 Billion by the year 2027, while Latin America will expand at a 3.7% CAGR through the analysis period. We bring years of research experience to this 16th edition of our report. The 203-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, AstraZeneca PLC; Boehringer Ingelheim GmbH; Chiesi Farmaceutici SpA; GlaxoSmithKline PLC; Mylan NV; Novartis International AG; Orion Corporation; Sunovion Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.
» Drug Class (Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Other Drug Classes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL